Stock Track | Amphastar Pharmaceuticals Shares Plunge on Disappointing Q3 Earnings, Cost Pressures

Stock Track11-07

Shares of Amphastar Pharmaceuticals Inc. (AMPH) took a nosedive on Tuesday, plummeting over 10% in after-hours trading, following the company's release of its third-quarter 2024 financial results. The sharp decline in stock price was driven by Amphastar's disappointing performance, with both revenue and earnings falling short of analysts' expectations.

For the quarter ended September 30, 2024, the pharmaceutical company reported revenue of $191.21 million, a 5.9% increase year-over-year but missing the consensus estimate of $194.69 million. Adjusted earnings per share (EPS) came in at $0.96, lower than the expected $1.01, highlighting the company's profitability challenges.

While Amphastar saw robust sales growth in key products like BAQSIMI, Primatene MIST, and epinephrine, these gains were partially offset by declines in the sales of glucagon, enoxaparin, and naloxone. Furthermore, the company faced significant cost pressures, including higher labor costs, increased component costs, and charges related to adjusting inventory and purchase commitments. These factors weighed heavily on Amphastar's gross margin, which contracted to 53.3% from 60% in the year-ago quarter, impacting overall profitability.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1166660071?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-07 22:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166660071","market":"hk","top_or_hot":-1,"title":"Stock Track | Amphastar Pharmaceuticals Shares Plunge on Disappointing Q3 Earnings, Cost Pressures","media":"Stock Track","content":"<p>Shares of Amphastar Pharmaceuticals Inc. (AMPH) took a nosedive on Tuesday, plummeting over 10% in after-hours trading, following the company's release of its third-quarter 2024 financial results. The sharp decline in stock price was driven by Amphastar's disappointing performance, with both revenue and earnings falling short of analysts' expectations.</p>\n\n<p>For the quarter ended September 30, 2024, the pharmaceutical company reported revenue of $191.21 million, a 5.9% increase year-over-year but missing the consensus estimate of $194.69 million. Adjusted earnings per share (EPS) came in at $0.96, lower than the expected $1.01, highlighting the company's profitability challenges.</p>\n\n<p>While Amphastar saw robust sales growth in key products like BAQSIMI, Primatene MIST, and epinephrine, these gains were partially offset by declines in the sales of glucagon, enoxaparin, and naloxone. Furthermore, the company faced significant cost pressures, including higher labor costs, increased component costs, and charges related to adjusting inventory and purchase commitments. These factors weighed heavily on Amphastar's gross margin, which contracted to 53.3% from 60% in the year-ago quarter, impacting overall profitability.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Amphastar Pharmaceuticals Shares Plunge on Disappointing Q3 Earnings, Cost Pressures</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Amphastar Pharmaceuticals Shares Plunge on Disappointing Q3 Earnings, Cost Pressures\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-07 22:37 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Amphastar Pharmaceuticals Inc. (AMPH) took a nosedive on Tuesday, plummeting over 10% in after-hours trading, following the company's release of its third-quarter 2024 financial results. The...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMPH","symbol_name":"Amphastar Pharmaceuticals","start_time":0,"source_url":"","article_id":"1166660071","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166660071","pubTimestamp":1730990226,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Amphastar Pharmaceuticals Inc.  took a nosedive on Tuesday, plummeting over 10% in after-hours trading, following the company's release of its third-quarter 2024 financial results. The sharp decline in stock price was driven by Amphastar's disappointing performance, with both revenue and earnings falling short of analysts' expectations.For the quarter ended September 30, 2024, the pharmaceutical company reported revenue of $191.21 million, a 5.9% increase year-over-year but missing the","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMPH":"Amphastar Pharmaceuticals"},"translate_title":"股票追踪Amphastar Pharmaceuticals股价因第三季度盈利令人失望和成本压力而暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMPH":1},"content_text":"Shares of Amphastar Pharmaceuticals Inc. (AMPH) took a nosedive on Tuesday, plummeting over 10% in after-hours trading, following the company's release of its third-quarter 2024 financial results. The sharp decline in stock price was driven by Amphastar's disappointing performance, with both revenue and earnings falling short of analysts' expectations.\nFor the quarter ended September 30, 2024, the pharmaceutical company reported revenue of $191.21 million, a 5.9% increase year-over-year but missing the consensus estimate of $194.69 million. Adjusted earnings per share (EPS) came in at $0.96, lower than the expected $1.01, highlighting the company's profitability challenges.\nWhile Amphastar saw robust sales growth in key products like BAQSIMI, Primatene MIST, and epinephrine, these gains were partially offset by declines in the sales of glucagon, enoxaparin, and naloxone. Furthermore, the company faced significant cost pressures, including higher labor costs, increased component costs, and charges related to adjusting inventory and purchase commitments. These factors weighed heavily on Amphastar's gross margin, which contracted to 53.3% from 60% in the year-ago quarter, impacting overall profitability.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1166660071"}